Evidence map›Paper›PMID 20466759›Full record

ArticleCarcinogenesis2010

Elevated NCOR1 disrupts PPARalpha/gamma signaling in prostate cancer and forms a targetable epigenetic lesion.

Sebastiano Battaglia, Orla Maguire, James L Thorne, Laura B Hornung, Craig L Doig, Song Liu, Lara E Sucheston, Anna Bianchi, Farhat L Khanim, Lyndon M Gommersall and 8 more

Open access · bronzeAbstract read
In one paragraph

Article in Carcinogenesis, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 64 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Nuclear Receptors and Lipid Sensing.Advances in experimental medicine and biology · 2022
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 2 countries.

Sebastiano BattagliaInstitute of Biomedical Research, Wolfson Drive, University of Birmingham Medical School, Edgbaston, B15 2TT, UK.
Orla Maguire
James L Thorne
Laura B Hornung
Craig L Doig
Song Liu
Lara E Sucheston
Anna Bianchi
Farhat L Khanim
Lyndon M Gommersall
Henry S O Coulter
Serena Rakha
Ian Giddings
Laura P O'Neill
Colin S Cooper
Christopher J McCabe
Christopher M Bunce
Moray J Campbell
University of Birmingham · GBInstitute of Cancer Research · GBRoswell Park Comprehensive Cancer Center · US

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Dean G. Tang · 1985 to 2026
$116.6M
Vitamin D in Prostate Cancer: Tumor Vasculature EffectsR01CA095045 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI JOHNSON, CANDACE S · 2002 to 2012
$3.2M
Vitamin D Analogs for Chemoprevention of Prostate CAncerR01CA095367 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI FOSTER, BARBARA A. · 2002 to 2012
$3.2M
Biotechnology and Biological Sciences Research Council BB/D523651/1Medical Research Council G0802851NCI NIH HHS 2R01-CA-095045-06NCI NIH HHS CA016056NCI NIH HHS P30 CA016056NCI NIH HHS R01 CA095045NCI NIH HHS R01 CA095367NCI NIH HHS R01 CA095367-06
6 · The paper itself

Abstract

The loss of anti-proliferative responsiveness in prostate cancer cell lines toward ligands for vitamin D receptor, retinoic acid receptors/retinoid X receptors and peroxisome proliferator activated receptor (PPAR)alpha/gamma may entail underlying epigenetic events, as ligand insensitivity reflects significantly altered messenger RNA expression of corepressors and histone-modifying enzymes. Expression patterns were dependent on phases of the cell cycle and associated with repressed basal gene expression of vitamin D receptor and PPARalpha/gamma target genes, for example CDKN1A [encodes p21((waf1/cip1))]. Elevated nuclear corepressor 1 (NCOR1) and nuclear corepressor 2/silencing mediator of retinoic acid and thyroid hormone receptor protein levels were detected in prostate cancer cell lines compared with non-malignant counterparts. Knockdown of the corepressor NCOR1 significantly elevated basal expression of a cohort of target genes, including CDKN1A. Both chemical [histone deacetylases inhibitor (HDACi)] and NCOR1 knockdown targeting enhanced anti-proliferative sensitivity toward PPARalpha/gamma ligands in prostate cancer cell lines. Pursuing PPARalpha/gamma signaling, microarray approaches were undertaken to identify pathways and genes regulated uniquely by a combination of PPARalpha/gamma activation and HDAC inhibition. Again, HDACi and knockdown approaches demonstrated that elevated NCOR1 expression and activity distorted PPARalpha/gamma gene targets centered on, for example cell cycle control, including CDKN1A and TGFBRAP1. Quantitative real time polymerase chain reaction validation and chromatin immunoprecipitation assays both confirmed that elevated NCOR1 disrupted the ability of PPARalpha/gamma to regulate key target genes (CDKN1A and TGFBRAP1). Interrogation of these relationships in prostate cancer samples using principal component and partial correlation analyses established significant interdependent relationships between NCOR1-PPARalpha/gamma and representative target genes, independently of androgen receptor expression. Therefore, we conclude that elevated NCOR1 distorts the actions of PPARalpha/gamma selectively and generates a potential epigenetic lesion with diagnostic and prognostic significance.

Indexed as

Epigenesis, GeneticApoptosisBiomarkers, TumorBlotting, WesternCell CycleCell ProliferationChromatin ImmunoprecipitationCyclin-Dependent Kinase Inhibitor p21Gene Expression ProfilingHistone Deacetylase InhibitorsHumansIntracellular Signaling Peptides and ProteinsMaleNuclear Receptor Co-Repressor 1Oligonucleotide Array Sequence AnalysisPPAR alphaBiomarkers, TumorCDKN1A protein, humanCyclin-Dependent Kinase Inhibitor p21Histone Deacetylase InhibitorsIntracellular Signaling Peptides and ProteinsNCOR1 protein, humanNuclear Receptor Co-Repressor 1PPAR alphaPPAR gammaReceptors, CalcitriolRNA, MessengerTGFBRAP1 protein, human

Identifiers

PMID20466759
PMCPMC2930800
OpenAlexW2134623198

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.